<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611218</url>
  </required_header>
  <id_info>
    <org_study_id>HD-FX-06-D</org_study_id>
    <nct_id>NCT03611218</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Clinical Performance of Dialyzers Applied During Post-dilution Online Hemodiafiltration</brief_title>
  <acronym>eMPORA II</acronym>
  <official_title>Comparative Safety and Clinical Performance of Dialyzers Applied During Post-dilution Online Hemodiafiltration - eMPORA II Study (Modified POlysulfone membRAne)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical Investigation will be performed to compare the safety and clinical performance
      profile of different hemodialyzers, all applied in on-line postdilution hemodiafiltration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to test whether the new FX P600 (applied during
      post-dilution online HDF) is non-inferior to two comparator dialyzers (Sureflux-17UX (Nipro)
      and Polyflux 170 H (Baxter/Gambro) in removing β2-microglobulin. The secondary objective is
      to exploratively compare the efficacy in removing other uremic solutes between the new FX
      P600 and the Sureflux-17UX as well as the Polyflux 170 H membranes. Additionally, the safety
      of the FX P600 dialyzer with a modified polysulfone membrane will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">December 8, 2018</completion_date>
  <primary_completion_date type="Actual">December 8, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Removal rate of β2-microglobulin</measure>
    <time_frame>t=240 minutes of HDF</time_frame>
    <description>Removal rate of β2-microglobulin will be calculated as primary endpoint in blood samples to evaluate the clinical performance of the new FX P600 dialyzer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of β2-microglobulin</measure>
    <time_frame>t=60 minutes of HDF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Removal rate of α1-microglobulin</measure>
    <time_frame>t=240 minutes of HDF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of α1-microglobulin</measure>
    <time_frame>t= 60 minutes of HDF</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Renal Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Hemodiafiltration HDF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dialyzer</intervention_name>
    <description>Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H</description>
    <arm_group_label>Hemodiafiltration HDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years

          -  Existing informed consent form signed and dated by study patient as well as
             investigator/authorized physician

          -  The patient is legally competent and able to understand the nature, risks, meaning,
             and consequences of the clinical trial and can subsequently declare his consent for
             participation in the clinical trial

          -  Patients with a chronic kidney disease stage 5D (end stage renal disease with a
             glomerular filtration rate of 15 ml/min or less) on hemodiafiltration as
             extracorporeal renal replacement therapy

        Exclusion Criteria:

          -  Any condition which could interfere with the patient's ability to comply with the
             study. This decision is at the discretion of the treating physician and relates to the
             general stable condition of the patient (e.g. absence of any acute condition, e.g.
             infection or mental problem which might give reason for concern etc.).

          -  Ongoing participation in an interventional clinical study during the preceding 30 days

          -  Previous participation in this study

          -  Pregnancy (pregnancy test will be conducted with female patients aged ≤ 55 years) or
             lactation period

          -  Patient is not able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-Haas-Dialysezentrum der PHV</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV-Dialysezentrum Goslar</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV Dialysezentrum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV-Dialysezentrum Lauterbach</name>
      <address>
        <city>Lauterbach</city>
        <zip>36341</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Hemodiafiltration</keyword>
  <keyword>Renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

